Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion: Laboratory investigation

Journal of Neurosurgery

Volumn 121, Issue 1, 2014, Pages 55-62

  Ratilal, Bernardo Oliveira ^a   Arroja, Mariana Moreira Coutinho ^b   Rocha, Joao Pedro Fidalgo ^b   Fernandes, Adelaide Maria Afonso ^b   Barateiro, Andreia Pereira ^b   Brites, Dora Maria Tuna Oliveira ^b   Pinto, Rui Manuel Amaro ^b   Sepodes, Bruno Miguel Nogueira ^b   Mota Filipe, Helder Dias ^b  

^a Universidade de Lisboa   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Neuroprotection; Rat; Recombinant human erythropoietin; Transient focal cerebral ischemia; Vascular disorders

Indexed keywords

NEURON SPECIFIC ENOLASE; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN PERFUSION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LASER DOPPLER FLOWMETRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SINGLE DRUG DOSE; WESTERN BLOTTING;

BBB = BLOOD-BRAIN BARRIER; BSA = BOVINE SERUM ALBUMIN; CBF = CEREBRAL BLOOD FLOW; CCA = COMMON CAROTID ARTERY; ECA = EXTERNAL CAROTID ARTERY; EPO, EPOR = ERYTHROPOIETIN, ERYTHROPOIETIN RECEPTOR; GSK-3Β = GLYCOGEN SYNTHASE KINASE-3Β; I/R = ISCHEMIA/REPERFUSION; ICA = INTERNAL CAROTID ARTERY; MCA = MIDDLE CEREBRAL ARTERY; NEUROPROTECTION; NF-ΚB = NUCLEAR FACTOR-KAPPA B; NSE = NEURON-SPECIFIC ENOLASE; PBS = PHOSPHATE-BUFFERED SALINE; PI3K = PHOSPHATIDYLINOSITOL 3-KINASE; RAT; RECOMBINANT HUMAN ERYTHROPOIETIN; RHEPO = RECOMBINANT HUMAN EPO; TRANSIENT FOCAL CEREBRAL ISCHEMIA; VASCULAR DISORDERS;

ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN; ERYTHROPOIETIN; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MALE; NEUROPROTECTIVE AGENTS; PHOSPHOPYRUVATE HYDRATASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR;

EID: 84903879102     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.2.JNS132197     Document Type: Article

References (43)

1. Ahmad O, Wardlaw J, Whiteley WN: Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review. Cerebrovasc Dis 33:47-54, 2012
2. Bahcekapili N, Uzüm G, Gökkusu C, Kuru A, Ziylan YZ: The relationship between erythropoietin pretreatment with bloodbrain barrier and lipid peroxidation after ischemia/reperfusion in rats. Life Sci 80:1245-1251, 2007
3. Banerjee D, Rodriguez M, Nag M, Adamson JW: Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 57:1895-1904, 2000 (Pubitemid 30252281)
4. Blasig IE, Mertsch K, Haseloff RF: Nitronyl nitroxides, a novel group of protective agents against oxidative stress in endothelial cells forming the blood-brain barrier. Neuropharmacology 43:1006-1014, 2002 (Pubitemid 35341236)
5. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526-10531, 2000
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857-868, 1999 (Pubitemid 29165088)
7. Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258-2263, 2002 (Pubitemid 34169048)
8. Chikuma M, Masuda S, Kobayashi T, Nagao M, Sasaki R: Tissue-specific regulation of erythropoietin production in the murine kidney, brain, and uterus. Am J Physiol Endocrinol Metab 279:E1242-E1248, 2000
9. Dame C, Langer J, Koller BM, Fauchère JC, Bucher HU: Urinary erythropoietin concentrations after early short-term infusion of high-dose recombinant Epo for neuroprotection in preterm neonates. Neonatology 102:172-177, 2012
10. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505, 2002 (Pubitemid 36337492)
11. Fischer AH, Jacobson KA, Rose J, Zeller R: Hematoxylin and eosin staining of tissue and cell sections. Cold Spring Harbor Protoc 5:1-2, 2008
12. Fu A, Hui EK, Lu JZ, Boado RJ, Pardridge WM: Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein. Brain Res 1369:203-207, 2011
13. Gao D, Ning N, Niu X, Dang Y, Dong X, Wei J, et al: Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am Heart J 164:715-727.e1, 2012
14. Gelderblom M, Daehn T, Schattling B, Ludewig P, Bernreuther C, Arunachalam P, et al: Plasma levels of neuron specific enolase quantify the extent of neuronal injury in murine models of ischemic stroke and multiple sclerosis. Neurobiol Dis 59:177-182, 2013
15. Gerriets T, Walberer M, Ritschel N, Tschernatsch M, Mueller C, Bachmann G, et al: Edema formation in the hyperacute phase of ischemic stroke. Laboratory investigation. J Neurosurg 111:1036-1042, 2009
16. Ha SK, Lim DJ, Seok BG, Kim SH, Park JY, Chung YG: Risk of stroke with temporary arterial occlusion in patients undergoing craniotomy for cerebral aneurysm. J Korean Neurosurg Soc 46:31-37, 2009
17. Harari OA, Liao JK: NF-κB and innate immunity in ischemic stroke. Ann N Y Acad Sci 1207:32-40, 2010
18. Hasselblatt M, Ehrenreich H, Sirén AL: The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 18:132-138, 2006 (Pubitemid 44510112)
19. Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T, et al: A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 30:961-968, 2010
20. Justicia C, Martín A, Rojas S, Gironella M, Cervera A, Panés J, et al: Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. J Cereb Blood Flow Metab 26:421-432, 2006
21. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA: Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate 85:138-144, 2004 (Pubitemid 38437682)
22. Khatri R, McKinney AM, Swenson B, Janardhan V: Bloodbrain barrier, reperfusion injury, and hemorrhagic transformation in acute ischemic stroke. Neurology 79 (13 Suppl 1):S52-S57, 2012
23. Liu K, Sun T, Wang P, Liu YH, Zhang LW, Xue YX: Effects of erythropoietin on blood-brain barrier tight junctions in ischemia-reperfusion rats. J Mol Neurosci 49:369-379, 2013
24. Lourbopoulos A, Karacostas D, Artemis N, Milonas I, Grigoriadis N: Effectiveness of a new modified intraluminal suture for temporary middle cerebral artery occlusion in rats of various weight. J Neurosci Methods 173:225-234, 2008
25. Maio R, Sepodes B, Patel NS, Thiemermann C, Mota-Filipe H, Costa P: Erythropoietin preserves the integrity and quality of organs for transplantation after cardiac death. Shock 35:126-133, 2011
26. Martínez-Estrada OM, Rodríguez-Millán E, González-De Vicente E, Reina M, Vilaró S, Fabre M: Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 18:2538-2544, 2003 (Pubitemid 37452669)
27. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R: A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269:19488-19493, 1994
28. Minnerup J, Heidrich J, Rogalewski A, Schäbitz WR, Wellmann J: The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 40:3113-3120, 2009
29. Prunier F, Bière L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, et al: Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J 163:200-207.e1, 2012
30. Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, et al: Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 19:919-926, 2006 (Pubitemid 44511117)
31. Shang Y, Wu Y, Yao S, Wang X, Feng D, Yang W: Protective effect of erythropoietin against ketamine-induced apoptosis in cultured rat cortical neurons: involvement of PI3K/Akt and GSK-3 beta pathway. Apoptosis 12:2187-2195, 2007 (Pubitemid 350077253)
32. Shen J, Wu Y, Xu JY, Zhang J, Sinclair SH, Yanoff M, et al: ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci 51:35-46, 2010
33. Signore AP, Weng Z, Hastings T, Van Laar AD, Liang Q, Lee YJ, et al: Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem 96:428-443, 2006
34. Silasi G, MacLellan CL, Colbourne F: Use of telemetry blood pressure transmitters to measure intracranial pressure (ICP) in freely moving rats. Curr Neurovasc Res 6:62-69, 2009
35. Sirén AL, Fasshauer T, Bartels C, Ehrenreich H: Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6:108-127, 2009
36. Sirén AL, Knerlich F, Poser W, Gleiter CH, Brück W, Ehrenreich H: Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol 101:271-276, 2001 (Pubitemid 32219761)
37. Spatz M: Past and recent BBB studies with particular emphasis on changes in ischemic brain edema: dedicated to the memory of Dr. Igor Klatzo. Acta Neurochir Suppl 106:21-27, 2010
38. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10:290-293, 1990 (Pubitemid 20096202)
39. Utepbergenov DI, Mertsch K, Sporbert A, Tenz K, Paul M, Haseloff RF, et al: Nitric oxide protects blood-brain barrier in vitro from hypoxia/ reoxygenation-mediated injury. FEBS Lett 424:197-201, 1998 (Pubitemid 28135313)
40. Velly L, Pellegrini L, Guillet B, Bruder N, Pisano P: Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword? Pharmacol Ther 128:445-459, 2010
41. Vogel J, Gassmann M: Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models. J Physiol 589:1259-1264, 2011
42. Walberer M, Ritschel N, Nedelmann M, Volk K, Mueller C, Tschernatsch M, et al: Aggravation of infarct formation by brain swelling in a large territorial stroke: a target for neuroprotection? Laboratory investigation. J Neurosurg 109:287-293, 2008
43. Xiong Y, Mahmood A, Qu C, Kazmi H, Zhang ZG, Noguchi CT, et al: Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor. J Neurotrauma 27:205-215, 2010